International Immunopharmacology · 2019 · 16 citations · 31 references
MedicineHematologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsPlatelet ActivationPlatelet PhysiologyPlatelet TransfusionPlatelet-to-lymphocyte RatioProgrammed Cell Death Ligand 1 InhibitionProgrammed Cell Death Protein 1 (Pd-1) PathwayProgrammed Cell Death Protein 1 InhibitorsProgrammed Death-ligand 1 BiomarkerProgrammed Death-ligand 1 Targeting
31
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. · New England Journal of Medicine · 2012 · 12.7K citations · Full text
Life Sciences, Immunology, Oncology +17
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei, L. Paz-Ares, Leora Horn et al. · New England Journal of Medicine · 2015 · 9.5K citations · Full text
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Edward B. Garon, Naiyer A. Rizvi, Rina Hui et al. · New England Journal of Medicine · 2015 · 6.2K citations · Full text
Medicine, Oncology, Pharmacology +17